Does Rallies show Form 4 insider transactions for NPCE?

Yes. Rallies tracks NPCE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NPCE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NPCE. It does not provide personalized investment advice.

NPCE (Neuropace, Inc. Common Stock) Stock Analysis - Insider Trades

Neuropace, Inc. Common Stock (NPCE) is a publicly traded Healthcare sector company. As of May 21, 2026, NPCE trades at $15.33 with a market cap of $545.16M and a P/E ratio of -24.63. NPCE moved +2.43% today. Year to date, NPCE is +2.59%; over the trailing twelve months it is -9.56%. Its 52-week range spans $5.45 to $19.60. Analyst consensus is strong buy with an average price target of $19.75. Rallies surfaces NPCE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NPCE stock inside the company?

Recent NPCE insider activity includes Morrell Martha sold 25.00K, ORBIMED ADVISORS LLC sold 134.14K, and ORBIMED ADVISORS LLC sold 34.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NPCE Key Metrics

Key financial metrics for NPCE
Metric	Value
Price	$15.33
Market Cap	$545.16M
P/E Ratio	-24.63
EPS	$-0.65
Dividend Yield	0.00%
52-Week High	$19.60
52-Week Low	$5.45
Volume	1
Avg Volume	0
Revenue (TTM)	$99.53M
Net Income	$-21.57M
Gross Margin	78.29%

Recent NPCE Insider Trades

Morrell Martha sold 25.00K (~$399.25K) on Dec 15, 2025.
ORBIMED ADVISORS LLC sold 134.14K (~$2.12M) on May 14, 2025.
ORBIMED ADVISORS LLC sold 34.00K (~$541.96K) on May 14, 2025.

Latest NPCE News

NeuroPace Q1 Sales Up 19.5%, Guidance Raised to 21–23% with $20 Price Target — May 15, 2026
NeuroPace narrows Q1 loss to $0.13 per share, beats estimates and ups revenue outlook — May 12, 2026
NeuroPace Shares Surge 6.3% to $18.12 on Heavy Volume, Q1 Revenue Seen $21.6M — May 11, 2026
NeuroPace Boosts Medicare RNS Reimbursement 44%, Forecasts $98M–$100M 2026 Revenue — Mar 10, 2026
NeuroPace Q4 Loss Narrows to $0.08, Revenues Jump 23.8% to $26.6M — Mar 3, 2026

NPCE Analyst Consensus

4 analysts cover NPCE: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.75.

Common questions about NPCE

Who is trading NPCE stock inside the company?: Recent NPCE insider activity includes Morrell Martha sold 25.00K, ORBIMED ADVISORS LLC sold 134.14K, and ORBIMED ADVISORS LLC sold 34.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NPCE?: Yes. Rallies tracks NPCE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NPCE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NPCE. It does not provide personalized investment advice.